Cargando…

Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients

Alterations in circulating Cu and Zn are negative predictors of survival in neoplastic patients and are known during lung cancer. However, no data on predicting mortality of lung cancer patients based on the level of these elements in the blood have been presented to date. The aims of this prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zabłocka-Słowińska, Katarzyna, Prescha, Anna, Płaczkowska, Sylwia, Porębska, Irena, Kosacka, Monika, Pawełczyk, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824662/
https://www.ncbi.nlm.nih.gov/pubmed/33375477
http://dx.doi.org/10.3390/nu13010060
_version_ 1783640132510810112
author Zabłocka-Słowińska, Katarzyna
Prescha, Anna
Płaczkowska, Sylwia
Porębska, Irena
Kosacka, Monika
Pawełczyk, Konrad
author_facet Zabłocka-Słowińska, Katarzyna
Prescha, Anna
Płaczkowska, Sylwia
Porębska, Irena
Kosacka, Monika
Pawełczyk, Konrad
author_sort Zabłocka-Słowińska, Katarzyna
collection PubMed
description Alterations in circulating Cu and Zn are negative predictors of survival in neoplastic patients and are known during lung cancer. However, no data on predicting mortality of lung cancer patients based on the level of these elements in the blood have been presented to date. The aims of this prospective cohort study were as follows: (i) To evaluate the disturbances in serum and whole blood Cu and Zn, (ii) to assess the relationships between serum and whole blood Cu and Zn status and clinical, sociodemographic, and nutritional data, and (iii) to investigate the association of Cu and Zn status with all-cause mortality in lung cancer. Naïve-treatment lung cancer patients (n = 167) were characterized in terms of sociodemographic, clinical, and anthropometric data and dietary intake and compared with sex-matched control subjects (n = 48). Whole blood and serum Cu and Zn status was determined by atomic absorption spectrometry. Cox proportional hazards models adjusted for multiple confounders/mediators were used to estimate the association between all-cause death and Cu and Zn status. Sex, cardiovascular disease, chronic obstructive pulmonary disease, clinical stage, and hemoglobin, platelet, and glucose concentrations significantly differentiated Cu and Zn status. All-cause mortality in lung cancer patients was positively associated with serum Cu levels, Cu:Zn ratio, and whole blood Zn levels. However, an advanced clinical stage of disease was the strongest predictor of all-cause mortality. Circulatory status of Cu and Zn might be included in routine clinical characteristics of patients with lung cancer patients as additional prognostic variables, but only after further more detail studies.
format Online
Article
Text
id pubmed-7824662
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78246622021-01-24 Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients Zabłocka-Słowińska, Katarzyna Prescha, Anna Płaczkowska, Sylwia Porębska, Irena Kosacka, Monika Pawełczyk, Konrad Nutrients Article Alterations in circulating Cu and Zn are negative predictors of survival in neoplastic patients and are known during lung cancer. However, no data on predicting mortality of lung cancer patients based on the level of these elements in the blood have been presented to date. The aims of this prospective cohort study were as follows: (i) To evaluate the disturbances in serum and whole blood Cu and Zn, (ii) to assess the relationships between serum and whole blood Cu and Zn status and clinical, sociodemographic, and nutritional data, and (iii) to investigate the association of Cu and Zn status with all-cause mortality in lung cancer. Naïve-treatment lung cancer patients (n = 167) were characterized in terms of sociodemographic, clinical, and anthropometric data and dietary intake and compared with sex-matched control subjects (n = 48). Whole blood and serum Cu and Zn status was determined by atomic absorption spectrometry. Cox proportional hazards models adjusted for multiple confounders/mediators were used to estimate the association between all-cause death and Cu and Zn status. Sex, cardiovascular disease, chronic obstructive pulmonary disease, clinical stage, and hemoglobin, platelet, and glucose concentrations significantly differentiated Cu and Zn status. All-cause mortality in lung cancer patients was positively associated with serum Cu levels, Cu:Zn ratio, and whole blood Zn levels. However, an advanced clinical stage of disease was the strongest predictor of all-cause mortality. Circulatory status of Cu and Zn might be included in routine clinical characteristics of patients with lung cancer patients as additional prognostic variables, but only after further more detail studies. MDPI 2020-12-27 /pmc/articles/PMC7824662/ /pubmed/33375477 http://dx.doi.org/10.3390/nu13010060 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zabłocka-Słowińska, Katarzyna
Prescha, Anna
Płaczkowska, Sylwia
Porębska, Irena
Kosacka, Monika
Pawełczyk, Konrad
Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients
title Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients
title_full Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients
title_fullStr Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients
title_full_unstemmed Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients
title_short Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients
title_sort serum and whole blood cu and zn status in predicting mortality in lung cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824662/
https://www.ncbi.nlm.nih.gov/pubmed/33375477
http://dx.doi.org/10.3390/nu13010060
work_keys_str_mv AT zabłockasłowinskakatarzyna serumandwholebloodcuandznstatusinpredictingmortalityinlungcancerpatients
AT preschaanna serumandwholebloodcuandznstatusinpredictingmortalityinlungcancerpatients
AT płaczkowskasylwia serumandwholebloodcuandznstatusinpredictingmortalityinlungcancerpatients
AT porebskairena serumandwholebloodcuandznstatusinpredictingmortalityinlungcancerpatients
AT kosackamonika serumandwholebloodcuandznstatusinpredictingmortalityinlungcancerpatients
AT pawełczykkonrad serumandwholebloodcuandznstatusinpredictingmortalityinlungcancerpatients